1. MARKETS
  2. SECTOR : PHARMA & BIOTECH
  3. INDUSTRY : MAJOR PHARMACEUTICALS
  4. BRISTOL-MYERS SQUIBB CO.
Bristol-Myers Squibb Co.
XNYS: BMY
Mid-range Performer
Download real time
59.700.11(0.18%)
40.40% Gain from 52W Low
11.0M
XNYS Volume

XNYS 07 Oct, 2026 5:30 PM (EDT)

Portfolio

Alert

My Notes

Bristol-Myers Squibb quarterly and annual earnings report: results, revenue, profit, P&L, balance sheet, cash flow, financial ratios, revenue mix, peer comparison, and financial documents

View Charts

Forecaster Analyst Estimates for Bristol-Myers Squibb share price target, revenues, EPS, net income and more

Bristol-Myers Squibb quarterly results: revenue, profit, and P&L – 13 quarter history

Nested row level
Base Level
Reporting Type
Originally Reported
Cell Data
Actual
Table Settings
YoY & New to Old
Nested row level
Base Level
Export
  • POSITIVE

    Quarterly Revenue Bristol-Myers Squibb Jun-2026 Quarterly Revenue is $12,973 Million which is growth of 5.7% YoY.

  • POSITIVE

    Quarterly Net Profit Bristol-Myers Squibb Jun-2026 Quarterly Net Profit is $3,317 Million which is growth of 153.2% YoY.

Bristol-Myers Squibb Co., Earnings Report - Quarterly Results, standalone, All financials are in USD Million and price data in USD
IndicatorGraphJun '26Mar '26Dec '25Sep '25Jun '25Mar '25Dec '24Sep '24Jun '24Mar '24Dec '23Sep '23Jun '23
Operating Rev.
12,97311,48912,50312,22212,26911,20112,34211,89212,20111,86511,47710,96611,226
Cost Of Rev.
3,7263,4214,0973,4353,3723,0334,8122,9573,2672,9322,7452,5062,876
Gross Profit
9,2478,0688,4068,7878,8978,1687,5308,9358,9348,9338,7328,4608,350
⌄
5,2224,7035,5935,1485,1234,6717,0206,7637,2437,4196,8296,5016,449
Operating Profit
4,0253,3652,8133,6393,7743,4975102,1721,6911,5141,9031,9591,901
⌄
-407-411-432-480-485-494-496-505-521-425-316-280-282
Profit Before Tax
4,0863,2401,4703,1141,7732,9711751,6761,286-11,5161,6742,1371,859
Tax
77056138491946050999461-398392-88203-218
⌄
3,3172,6771,0872,2011,3102,456721,2111,680-11,9111,7621,9282,073
Diluted NI Avail to Com Stockholders Ann.
3,3172,6771,0872,2011,3102,456721,2111,680-11,9111,7621,9282,073
Basic EPS
1.61.30.51.10.61.200.60.8-5.90.90.91
Diluted EPS After ExtraOrdinary
1.51.31.11.31.41.40.20.71-1.11.111.1
Number Of Shares End
2,0422,0382,0342,0362,0352,0312,0302,0282,0272,0232,0272,0572,093
Net Income Continuing Discontinued Operations
3,3172,6771,0872,2011,3102,456721,2111,680-11,9111,7621,9282,073
Normalized Income
3,093.82,581.12,2752,594.32,781.62,921.1292.11,464.81,934.4-2,238.42,135.42,024.82,285.3
Interest Income
-------------
Interest
407411432480485494496505521425316280282
Net Interest Income
-407-411-432-480-485-494-496-505-521-425-316-280-282
EBIT
4,4933,6511,9023,5942,2583,4656712,1811,807-11,0911,9902,4172,141
EBITDA
5,0874,2452,8794,6053,2694,4772,5514,7734,403-8,5594,4544,8524,573
Reconciled Cost Of Rev.
3,5693,2643,9463,2553,1912,8514,6252,7713,0872,7572,5592,3272,701
Reconciled Depr.
5945949771,0111,0111,0121,8802,5922,5962,5322,4642,4352,432
Profit From Continuing Operations
3,3162,6781,0852,1951,3132,462761,2151,684-11,9081,7621,9342,077
Normalized EBITDA
4,8124,1294,4875,1635,2555,0382,8475,1234,7454,4474,9574,9594,859
*All financials are in USD Million and price data in USD
Add metric to table
Search...

Bristol-Myers Squibb competitor comparison and performance snapshot within industry

Bristol-Myers Squibb annual results: revenue, profit, P&L, and margins as of Dec 2025 – 11 year history

Nested row level
Base Level
Reporting Type
Originally Reported
Cell Data
Actual
Table Settings
YoY & New to Old
CAGR Columns
Select...
Nested row level
Base Level
Export
  • NEGATIVE

    Annual Revenue Bristol-Myers Squibb Dec-2025 Annual Revenue is $48,195 Million which is growth of -0.2% YoY.

  • POSITIVE

    Annual Net Profit Bristol-Myers Squibb Dec-2025 Annual Net Profit is $7,054 Million which is growth of 178.8% YoY.

Bristol-Myers Squibb Co., Earnings Report - Annual Results, standalone, All financials are in USD Million and price data in USD
IndicatorGraphCAGR 3 YrsCAGR 5 YrsTTMDec '25Dec '24Dec '23Dec '22Dec '21Dec '20Dec '19Dec '18Dec '17Dec '16Dec '15
⌄
1.4%
2.5%
 48,19548,30045,00646,15946,38542,51826,14522,56120,77619,42716,560
Cost Of Rev. Ann.
11.2%
3.4%
14,67913,93613,96810,69310,1379,94011,7738,0786,5476,0664,9463,909
Gross Profit Ann.
-1.7%
2.2%
34,50834,25934,33234,31336,02236,44530,74518,06716,01414,71014,48112,651
Operating Exp. Ann.
-8.6%
-6.4%
20,66620,53528,44526,11826,91829,05228,55513,75310,86911,2609,94210,921
Operating Profit Ann.
14.7%
44.3%
13,84213,7245,8878,1959,1047,3932,1904,3145,1453,4504,5391,730
⌄
-
-
-1,730-1,891-1,947-1,166-1,232-1,334-1,420-656-183-196-167-184
Other Exp. Ann.
-
-
 -2,504-12,3191,411-1592,039-7,6411,3171,0061,8771,543531
PBT Ann.
6.5%
-
11,9109,328-8,3798,4407,7138,098-6,8714,9755,9685,1315,9152,077
Tax Ann.
18.4%
1.4%
2,6342,2725544001,3681,0842,1241,5151,0214,1561,408446
⌄
3.7%
-
9,2827,054-8,9488,0256,3276,994-9,0153,4394,9201,0074,4571,565
Diluted NI Avail to Com Stockholders Ann.
3.7%
-
9,2827,054-8,9488,0256,3276,994-9,0153,4394,9201,0074,4571,565
EPS Ann.
5.3%
-
 3.5-4.43.933.2-4230.62.70.9
Diluted EPS Ann.
5.3%
-
 3.5-4.43.933.1-4230.62.70.9
Number Of Shares End
-1.2%
-2%
 2,0342,0302,0272,1092,2032,2521,9181,6331,6361,6741,670
Total Exp. Ann.
-2.4%
-3.1%
 34,47142,41336,81137,05538,99240,32821,83117,41617,32614,88814,830
Net Income Continuing Discontinued Operations Ann.
3.7%
-
9,2827,054-8,9488,0256,3276,994-9,0153,4394,9201,0074,4571,565
Normalized Income Ann.
9.3%
-
10,544.210,620.61,459.38,818.98,124.46,787-2,188.83,686.44,853.7768.24,102.71,700.8
Interest Income Ann.
-
-
 -----------
Interest Ann.
15.4%
5.9%
1,7301,8911,9471,1661,2321,3341,420656183196167184
EBITDA Ann.
-7.5%
25.3%
16,81615,2303,16819,36619,22120,1184,9297,3776,7886,1166,4642,637
Reconciled Cost Of Rev. Ann.
11.9%
3.6%
14,03413,24213,2409,9809,4569,27711,0817,4676,5476,0664,9463,909
Reconciled Depr. Ann.
-26.9%
-17.3%
3,1764,0119,6009,76010,27610,68610,3801,746637789382376
Profit From Continuing Operations Ann.
3.6%
-
9,2747,055-8,9338,0406,3457,014-8,9953,4604,9479754,5071,631
Normalized EBITDA Ann.
-2.3%
6.9%
18,59119,94517,16220,19921,40519,87914,2807,7336,7085,7185,9992,810
*All financials are in USD Million and price data in USD
Add metric to table
Search...
Total Rev. Ann.
1Y CHG
-0.2%
2Y CAGR
3.5%
3Y CAGR
1.4%
5Y CAGR
2.5%
7Y CAGR
11.5%
10Y CAGR
11.3%
Total Revenue Annual is falling faster than historical averages.
Net Profit Ann.
2Y CAGR
-6.2%
3Y CAGR
3.7%
7Y CAGR
5.3%
10Y CAGR
16.2%
Net Profit Annual growth is stable compared to historical averages.
Operating Exp. Ann.
1Y CHG
-27.8%
2Y CAGR
-11.3%
3Y CAGR
-8.6%
5Y CAGR
-6.4%
7Y CAGR
9.5%
10Y CAGR
6.5%
Operating Expenses Annual Cr is falling faster than historical averages.

Bristol-Myers Squibb balance sheet as of Dec 2025: assets, liabilities, reserves, and borrowings – 11 year history

Nested row level
Base Level
Reporting Type
Originally Reported
Cell Data
Actual
Table Settings
YoY & New to Old
CAGR Columns
Select...
Nested row level
Base Level
Export
  • POSITIVE

    Total Shareholders Fund Bristol-Myers Squibb Dec-2025 Total Shareholders Fund is $18,473 Million which is growth of 13.1% YoY.

  • NEGATIVE

    Total Assets Bristol-Myers Squibb Dec-2025 Total Assets is $90,038 Million which is growth of -2.8% YoY.

Bristol-Myers Squibb Co., Balance Sheet, standalone, All financials are in USD Million and price data in USD
IndicatorGraphCAGR 3 YrsCAGR 5 YrsDec '25Dec '24Dec '23Dec '22Dec '21Dec '20Dec '19Dec '18Dec '17Dec '16Dec '15
⌄
-2.4%
-5.3%
90,03892,60395,15996,820109,314118,481129,94434,98633,55133,70731,748
⌄
2.9%
-2.4%
71,53276,21565,67465,70273,30880,59978,24620,85921,70417,36017,324
⌄
-15.9%
-13.4%
18,47316,33529,43031,06135,94637,82251,59814,03111,74116,17714,266
Total Capitalization Ann.
-2.5%
-6.6%
61,32363,93866,08366,11775,55186,15894,98519,67718,71621,89320,816
Tangible Assets Ann.
-
-
-22,634-29,027-19,224-26,443-27,331-35,968-34,8596,4023,6687,9175,966
Working Capital Ann.
3.5%
-11.7%
5,9736,0069,5085,38311,39411,11211,0506,5065,2914,8632,398
Invested Capital Ann.
-3.3%
-6.4%
63,58465,98469,20270,38180,49988,49898,33121,38019,70322,88520,955
Tangible Book Value Ann.
-
-
-22,634-29,027-19,224-26,443-27,331-35,968-34,8596,4023,6687,9175,966
Borrowings Ann.
5%
-1.8%
47,13951,20041,46440,71745,59651,67347,5387,3497,9626,7086,689
Net Debt Ann.
4.9%
-0.7%
34,90239,30328,30830,19730,57436,13034,3874382,5412,4714,304
Share Issued Ann.
0.3%
0.2%
2,922.82,9232,9232,9002,9002,9002,9002,2002,2002,2002,200
Number Of Shares End
-1.2%
-2%
2,0342,0302,0272,1092,2032,2521,9181,6331,6361,6741,670
*All financials are in USD Million and price data in USD
Add metric to table
Search...
Total Assets Ann.
1Y CHG
-2.8%
2Y CAGR
-2.7%
3Y CAGR
-2.4%
5Y CAGR
-5.3%
7Y CAGR
14.5%
10Y CAGR
11%
Total Assets Annual is falling faster than historical averages.
Total Current Liabilities Ann.
1Y CHG
-1.5%
2Y CAGR
2.6%
3Y CAGR
2.3%
5Y CAGR
4.2%
7Y CAGR
11.9%
10Y CAGR
11.3%
Total Current Liabilities Annual Cr is falling faster than historical averages.
Total ShareHolders Funds Ann.
1Y CHG
13.1%
2Y CAGR
-20.8%
3Y CAGR
-15.9%
5Y CAGR
-13.4%
7Y CAGR
4%
10Y CAGR
2.6%
Total ShareHolders Funds Annual growth is higher than historical averages.

Bristol-Myers Squibb ROE, ROCE, book value, and debt-to-equity ratio as of Dec 2025 – 11 year history

Nested row level
Base Level
Reporting Type
Originally Reported
Cell Data
Actual
Table Settings
YoY & New to Old
CAGR Columns
Select...
Nested row level
Base Level
Export
  • POSITIVE

    Book Value Per Share Bristol-Myers Squibb Book Value Per Share is $11 which is growth of 27.6% YoY.

  • NEUTRAL

    ROE Bristol-Myers Squibb ROE is 0% which is growth of 0% YoY.

Bristol-Myers Squibb Co., Ratios, standalone, All financials are in USD Million and price data in USD
IndicatorGraphCAGR 3 YrsCAGR 5 YrsDec '25Dec '24Dec '23Dec '22Dec '21Dec '20Dec '19Dec '18Dec '17Dec '16Dec '15
RoA Ann. %
-
-
--9.53%8.36%6.14%6.14%-7.26%4.17%14.36%2.99%13.62%4.78%
ROE Ann. %
-
-
--39.10%26.53%18.88%18.96%-20.16%10.48%38.18%7.21%29.28%10.75%
ROIC %
-
-
-0.72.93.13.2-10.5-1.25.7-10.74.1-0.8
OPM Ann. %
13%
40.8%
28.48%12.19%18.21%19.72%15.94%5.15%16.50%22.80%16.61%23.36%10.45%
Inventory Turnover Ratio Ann.
-
-
-5.44.34.64.83.72.95.6542.8
Asset Turnover Ann. %
-
-
-0.50.50.50.40.30.30.70.60.60.5
Working Capital Turnover Ann.
-2%
16.3%
8.184.78.64.13.82.43.53.946.9
Quick Ratio Ann.
-
-
-1.11.21.11.41.31.31.41.41.41.1
Current Ratio Ann.
-
-
-1.31.41.31.51.61.61.61.61.61.3
Interest Coverage Ratio Ann.
-
-
--3.38.27.37.1-3.88.633.627.236.412.3
LT Debt To Equity Ann.
-
-
-31.31.21.11.30.90.40.60.40.5
*All financials are in USD Million and price data in USD
Add metric to table
Search...

Bristol-Myers Squibb cash flow: net, operating, investing, and financing flows as of Dec 2025 – 11 year history

Nested row level
Base Level
Reporting Type
Originally Reported
Cell Data
Actual
Table Settings
YoY & New to Old
CAGR Columns
Select...
Nested row level
Base Level
Export
  • NEGATIVE

    Cash From Operating Activity Bristol-Myers Squibb Dec-2025 Cash From Operating Activity is $14,156 Million which is growth of -6.8% YoY.

  • POSITIVE

    Net Cash Flow Bristol-Myers Squibb Dec-2025 Net Cash Flow is $-324 Million which is growth of 68.7% YoY.

Bristol-Myers Squibb Co., Cash Flow, standalone, All financials are in USD Million and price data in USD
IndicatorGraphCAGR 3 YrsCAGR 5 YrsDec '25Dec '24Dec '23Dec '22Dec '21Dec '20Dec '19Dec '18Dec '17Dec '16Dec '15
⌄
2.7%
0.1%
14,15615,19013,86013,06616,20714,0528,0675,9405,2752,8501,832
⌄
-
-
-4,132-21,352-2,295-1,062-538-10,859-9,770-874-661,480-1,572
⌄
-
-
-10,3485,127-9,416-16,962-16,224-1,1517,621-3,535-4,077-2,445-3,351
Cash Plus Cash Eqv. End Of Year Ann.
3.1%
-7.4%
10,21810,34711,5199,32514,31614,97312,8206,9115,4214,2372,385
Net Increase In Cash Plus Cash Eqv.s Ann.
-
-
-324-1,0352,149-4,958-5552,0425,9181,5311,1321,885-3,091
Cash Plus Cash Eqv. Begin Of Year Ann.
-10.3%
-4.2%
10,34711,5199,32514,31614,97312,8206,9115,4214,2372,3855,571
Income Tax Paid Supplemental Data Ann.
-
-
-----------
Interest Paid Supplemental Data Ann.
-
-
-----------
Capex Ann.
-
-
-1,311-1,248-1,209-1,118-973-753-836-951-1,055-1,215-820
Issuance Of Capital Stock Ann.
-
-
---------181266
Issuance Of Debt Ann.
-0.9%
-3.7%
5,76515,9694,4555,9266,94526,7781,4881,268
Repayment Of Debt Ann.
-
-
-10,940-5,873-3,879-11,431-6,022-2,750-9,256-5-1,224-15-1,957
Repurchase Of Capital Stock Ann.
-
-
-5,155-8,001-6,287-1,546-7,300-320-2,469-231
Free Cash Flow Ann.
2.4%
-0.7%
12,84513,94212,65111,94815,23413,2997,2314,9894,2201,6351,012
*All financials are in USD Million and price data in USD
Add metric to table
Search...
Cash from Operating Act. Ann.
1Y CHG
-6.8%
2Y CAGR
1.1%
3Y CAGR
2.7%
5Y CAGR
0.1%
7Y CAGR
13.2%
10Y CAGR
22.7%
Cash from Operating Activity Annual is falling faster than historical averages.
×